(Overview) New Biomarkers in a Novel Antibody-drug Conjugate for Triple Negative Breast Cancer

Aiko Nagayama, MD, PhD
Massachusetts General Hospital

Triple negative breast cancer (TNBC), defined by the lack of hormone receptors and the absence of HER2 overexpression, represents 15% to 20% of all breast cancers and has heterogeneous biology with poor prognosis. There is no approved targeted therapy for TNBC, which calls for a better treatment option. Here we report progress in ongoing studies involving (a) potential biomarkers identified in the profile of serial biopsy TNBC samples from patients who were treated with IMMU-132 and (b) the synthetic lethal target screening by whole genome CRISPR/Cas9 knockout library in human TNBC cell line models.

This is a brief overview of her talk that occurred during the 2018 Chabner Colloquium.

These lectures are designed to meet the educational needs of physicians and scientists in academic and practice settings who wish to advance their knowledge of the research into new treatments and improve their competence in the care of patients with cancer.

About The Chabner Colloquium:
Chaired by: Bruce A. Chabner, MD
Massachusetts General Hospital Cancer Center, Harvard Medical School.

This annual Colloquium is held in collaboration with The Massachusetts General Hospital Cancer Center and designed to focus on topics that bring cancer biology to clinical application:
- New targets and targeted agents
- Strategies for profiling and selection of patients for targeted drug trials
- Biomarkers and animal models to guide clinical development